There were no significant difference in time to resolution of DKA in the patients with type 1 and type 2 diabetes. Median time to resolution of DKA was 12 h with an optimized BHB cut-off value of < 1 mmol/L. The serum BHB level of < 1 mmol/L had 73.7% sensitivity and 100% specificity to predict DKA resolution. The serum BHB levels corresponding to HCO 3 levels for DKA severity were 4.5, 5.7, and 5.9 mmol/L in mild, moderate, and severe DKA, respectively. Serum BHB during treatment of DKA was significantly correlated with changes in serum bicarbonate ( r = − 0.64), serum anion gap ( r = 0.84), and venous pH ( r = − 0.6). The initial laboratories evaluation of patients did not significant differ between type1 and type2 diabetes. However, there was no significant difference in mortality between type1 and type2 diabetes. T1DM patients had more severe DKA more hypokalemia during treatment. while infection was the most common precipitating factor in T2DM (43.4%), non-compliance with treatment was the most common precipitating factor in T1DM (43.5%).

ResultsĪ total of 99 diabetes patients were diagnosed with DKA (mean age 39.4 years, 63.4% female, 53.6% T2DM).

The correlations between serum BHB, measured by the Ranbut assay, and pH, bicarbonate, and anion gap were examined. This prospective observational study of type 1 or type 2 diabetes mellitus who were diagnosed with DKA between 01 October 2018 and 30 September 2020. The aim of this study was to determine the differences in biochemical parameters and diabetic ketoacidosis (DKA) severity in adult patients with type 1 and type 2 diabetes and utilization of serum BHB as a biomarker for DKA resolution was also evaluated.

Raskin resolution